Liquidia Corp (LQDA) Q3 2025 10-Q Quarterly Report
Liquidia Corp (LQDA) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 3, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Liquidia Corp Q3 2025 10-Q Analysis
Risk Factors
- • New legal risk: United Therapeutics lawsuits seeking injunction to remove YUTREPIA from PAH/PH-ILD markets, risking loss of FDA approval or sales suspension
- • Most material update: Accumulated deficit $640.9M as of Sep 30, 2025, net losses $83.5M (9 months 2025) versus $128.3M (2024) and $78.5M (2023), ongoing loss uncertainty
Liquidia Corp Q3 2025 Quarterly FinancialsXBRL
Revenue
$54M
▲ +1121.7% YoY▲ +514.9% QoQ
Net Income
-$4M
▲ +84.7% YoY▲ +91.5% QoQ
Operating Margin
3.3%
▲ +65948bp YoY▲ +42766bp QoQ
Net Margin
-6.5%
▲ +51407bp YoY▲ +46401bp QoQ
ROE
-16.0%
Total Assets
$276M
EPS (Diluted)
$-0.03
▲ +89.7% YoY▲ +93.9% QoQ
Operating Cash Flow
-$10M
▲ +61.0% YoY▲ +75.3% QoQ
Source: XBRL data from Liquidia Corp Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Liquidia Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.